At ASM Microbe 2025, researchers underscore the role of NAAT in outpatient CDI diagnosis and raise concerns over PPI-related risk in older, healthcare-associated cases.
Clostridium difficile bacterium
Image credits: Unsplash
At ASM Microbe 2025, investigators from St Marianna University School of Medicine (Kawasaki, Japan) presented findings from a 10-year retrospective study examining community-onset Clostridioides difficile infection (CDI) among outpatients, a population less studied in the CDI epidemiologic landscape. The study was shared during Session CIV-P-201, focused on adult infectious diseases.
The research analyzed patients who underwent CDI testing at the institution’s outpatient department between March 2013 and April 2023, including glutamate dehydrogenase (GDH), toxin assays, and nucleic acid amplification tests (NAATs). CDI diagnosis was defined as GDH-positive with either toxin or NAAT positivity.
Out of 392 GDH/toxin tests, 48 (12.2%) were GDH-positive, and 11 (2.8%) were toxin-positive. Of six GDH-positive/toxin-negative cases tested via NAAT, three returned positive, leading to a total of 14 confirmed outpatient CDI cases. These results suggest a CDI positivity rate of 3.6% when including all diagnostic modalities.
The median age of CDI patients was 75 years (IQR: 29.25–80.75), and 64% were female. The most common underlying condition was gastrointestinal malignancy (21%). According to the MN severity criteria, 57% of infections were mild, 36% moderate, and 7% severe. Notably, 93% of patients received treatment, with metronidazole used most frequently (64%), followed by oral vancomycin (21%) and fidaxomicin (7%).
CDI can occur in outpatient settings, with 14 cases identified over 10 years using a combination of GDH, toxin, and NAAT testing.
Community-onset healthcare facility-associated CDI patients were older, more likely to be female, and exhibited higher disease severity than community-associated cases.
High rates of PPI use, especially in CO-HCFA-CDI patients, raise concerns about its prolonged role as a CDI risk factor even after discontinuation.
When stratified by infection classification, community-onset healthcare facility-associated CDI (CO-HCFA-CDI) cases (n=8) were older (median age 80.5 vs. 22 years) and more likely to be female (75% vs 40%) than community-associated CDI (CA-CDI) cases (n=5). Disease severity skewed higher in the CO-HCFA group, with 63% presenting with moderate infection and none with severe disease, compared to 20% severe cases in the CA-CDI group.
A notable risk factor was proton pump inhibitor (PPI) use, reported in 75% of CO-HCFA-CDI patients versus only 20% in the CA-CDI group. Given the known long-term association between PPIs and CDI, even up to a year post-discontinuation, this disparity raises ongoing concerns about outpatient PPI overuse and residual infection risk, particularly among older adults with prior healthcare exposure.
The investigators concluded that NAAT plays a valuable role in confirming CDI in GDH-positive/toxin-negative cases, especially in outpatient settings where rapid, accurate diagnosis is critical. These findings support more vigilant CDI surveillance in non-hospitalized populations, especially those with prior healthcare contact or ongoing medication risk factors.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
